Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Polycythemia vera: scientific advances and current practice.

Ayalew Tefferi1, Jerry L Spivak

  • 1Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA. tefferi.ayalew@mayo.edu

Seminars in Hematology
|October 8, 2005
PubMed
Summary

Polycythemia vera (PV) is a clonal disorder characterized by excess red blood cells. The JAK2 V617F mutation is associated with PV pathogenesis but not diagnostic alone.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Monocytosis in polycythemia vera: Clinical and molecular correlates.

American journal of hematology·2017
Same author

Socioeconomic burden of participation in clinical trials in patients with myeloproliferative neoplasms.

European journal of haematology·2017
Same author

Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia.

American journal of hematology·2017
Same author

Downregulation of GATA1 drives impaired hematopoiesis in primary myelofibrosis.

The Journal of clinical investigation·2017
Same author

The prognostic relevance of serum lactate dehydrogenase and mild bone marrow reticulin fibrosis in essential thrombocythemia.

American journal of hematology·2017
Same author

Diagnostic impact of the 2016 revised who criteria for polycythemia vera.

American journal of hematology·2017

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Polycythemia vera (PV) is a clonal hematopoietic stem cell disorder.
  • Its etiology is unknown, with no curative therapy besides bone marrow transplantation.
  • PV is more common than chronic myelogenous leukemia, particularly in individuals of Ashkenazi Jewish ancestry.

Purpose of the Study:

  • To review the current understanding of Polycythemia vera (PV) pathogenesis and diagnosis.
  • To discuss the role of the JAK2 V617F mutation in PV and related myeloproliferative disorders.
  • To highlight areas of agreement and controversy in PV management.

Main Methods:

  • Review of existing literature on Polycythemia vera (PV).
  • Analysis of diagnostic criteria, including red cell mass and serum erythropoietin levels.

Related Experiment Videos

  • Evaluation of the JAK2 V617F mutation's diagnostic utility.

    • Main Results:

    • PV is characterized by erythropoietin-independent erythroid colony formation.
    • The JAK2 V617F mutation is frequently found in PV and induces constitutive signaling.
    • JAK2 V617F is also present in other myeloproliferative disorders, complicating diagnosis.

    Conclusions:

    • The JAK2 V617F mutation is implicated in PV pathogenesis but is not sufficient for diagnosis.
    • Differential diagnosis of PV requires consideration of other myeloproliferative neoplasms.
    • Phlebotomy, aspirin, and cytoreductive therapy are mainstays of PV treatment.